Shares of Surmodics (SRDX) experienced a notable surge after a pivotal pre-trial hearing regarding the Federal Trade Commission's lawsuit, which seeks to prevent GTCR's acquisition of the company. In response, Surmodics has proposed the divestiture of select assets, possibly including its Biocoat business, as a strategic move to mitigate antitrust concerns surrounding the $627 million deal.
https://www.gurufocus.com/news/3006571/surmodics-srdx-shares-climb-12-amid-ftc-pretrial-hearing
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.